Theravance Biopharma Inc (TBPH) — Cash Flow-to-Debt Ratio
Theravance Biopharma Inc (TBPH) has a Cash Flow-to-Debt Ratio of -0.03x as of December 2025, meaning its operating cash flow of $-6.06 Million could theoretically repay 0% of its total liabilities ($188.85 Million) in one year. Explore long-term investment intensity of Theravance Biopharma Inc to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Theravance Biopharma Inc Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Theravance Biopharma Inc across 15 annual periods. Also explore how large is Theravance Biopharma Inc's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Theravance Biopharma Inc (2011–2025)
Year-by-year debt coverage analysis for Theravance Biopharma Inc. For market capitalisation and broader financial context, see Theravance Biopharma Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 1.26x | $238.54 Million | $188.85 Million | ▲ +2055.9% |
| 2024 | -0.06x | $-11.54 Million | $178.62 Million | ▲ +59.6% |
| 2023 | -0.16x | $-27.00 Million | $169.00 Million | ▲ +85.9% |
| 2022 | -1.13x | $-186.99 Million | $165.60 Million | ▼ -287.5% |
| 2021 | -0.29x | $-207.86 Million | $713.39 Million | ▲ +10.1% |
| 2020 | -0.32x | $-250.40 Million | $772.81 Million | ▲ +13.9% |
| 2019 | -0.38x | $-238.20 Million | $632.67 Million | ▼ -104.1% |
| 2018 | -0.18x | $-112.87 Million | $611.82 Million | ▲ +70.1% |
| 2017 | -0.62x | $-201.05 Million | $326.22 Million | ▼ -79.9% |
| 2016 | -0.34x | $-98.99 Million | $289.02 Million | ▲ +88.4% |
| 2015 | -2.96x | $-168.86 Million | $57.05 Million | ▲ +18.9% |
| 2014 | -3.65x | $-175.16 Million | $47.98 Million | ▼ -27.4% |
| 2013 | -2.87x | $-120.96 Million | $42.21 Million | ▲ +45.5% |
| 2012 | -5.25x | $-119.11 Million | $22.67 Million | ▼ -873.2% |
| 2011 | -0.54x | $-83.43 Million | $154.54 Million | — |